Eriodictyol attenuates arsenic trioxide-induced liver injury by activation of Nrf2

Guanghong Xie; Xiaolin Meng; Fei Wang; Yuxin Bao; Junyuan Huo

doi:10.18632/oncotarget.19822

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Eriodictyol attenuates arsenic trioxide-induced liver injury by activation of Nrf2

Guanghong Xie _, Xiaolin Meng, Fei Wang, Yuxin Bao and Junyuan Huo

PDF | HTML | How to cite

Oncotarget. 2017; 8:68668-68674. https://doi.org/10.18632/oncotarget.19822

Metrics: PDF 1547 views | HTML 2039 views | ?

Abstract

Guanghong Xie1,*, Xiaolin Meng1,*, Fei Wang1, Yuxin Bao1 and Junyuan Huo1

1College of Veterinary Medicine, Jilin University, Changchun 130062, China

*These authors have contributed equally to this work

Correspondence to:

Guanghong Xie, email: [email protected]

Keywords: eriodictyol, arsenic trioxide, liver injury, Nrf2

Received: March 29, 2017 Accepted: June 28, 2017 Published: August 02, 2017

ABSTRACT

Arsenic, a well-known human carcinogen, has been reported to induce hepatic oxidative stress and hepatic injury. Eriodictyol, a flavonoid found in citrus fruits, has been reported to have antioxidant effects. In this study, we aimed to investigate the protective effects of eriodictyol on arsenic trioxide (As₂O₃)-induced liver injury and to clarify the molecular mechanism. Male Wistar rats were administrated 3mg/kg As₂O₃ intravenous injection at days 1, 4, 5, and 7. Eriodictyol was given 1 h before or after As₂O₃ treatment. The results showed that eriodictyol prevented As₂O₃-induced liver reactive oxygen species (ROS) and malonaldehyde (MDA) levels. Eriodictyol abrogated As₂O₃-induced decrease of the antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GPX), and catalase (CAT) activity. Eriodictyol also attenuated As₂O₃-induced hepatic pathological damage. In addition, eriodictyol promoted the expression of nuclear factor erythroid 2 p45 related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) up-regulated by As₂O₃. In conclusion, our results demonstrated that eriodictyol exhibited a protective effect on As₂O₃-induced liver injury and the possible mechanism is involved in activating Nrf2 signaling pathway.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19822

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Eriodictyol attenuates arsenic trioxide-induced liver injury by activation of Nrf2

Abstract